Speratum Biopharma
Speratum Biopharma is dedicated to transforming cancer treatment through innovative microRNA-based therapies and RNA technologies. Founded in 2014, the company leverages proprietary platforms such as Nano-In™, NoPass™, and miR-198 to develop targeted, effective therapeutics for solid tumors and other diseases. With a focus on precision medicine, Speratum aims to deliver safe, scalable, and life-changing treatments. The company is actively involved in research, clinical trials, and collaborations to advance oncology and infectious disease therapeutics, with a mission to deliver hope through innovation and scientific excellence.
Industries
Nr. of Employees
small (1-50)
Speratum Biopharma
Products
Lead miRNA-198 mimic therapeutic candidate
A microRNA-198 mimic formulated in a polymer nanoparticle delivery system designed to restore tumor-suppressor microRNA activity, reduce tumor burden, and sensitize tumors to chemotherapy in preclinical solid-tumor models.
Lead miRNA-198 mimic therapeutic candidate
A microRNA-198 mimic formulated in a polymer nanoparticle delivery system designed to restore tumor-suppressor microRNA activity, reduce tumor burden, and sensitize tumors to chemotherapy in preclinical solid-tumor models.
Services
Clinical investigator network support
Recruitment, onboarding, and operational support for physician investigators and clinical trial sites, including training and study resources to facilitate participation in investigational trials.
Clinical investigator network support
Recruitment, onboarding, and operational support for physician investigators and clinical trial sites, including training and study resources to facilitate participation in investigational trials.
Expertise Areas
- Precision oncology
- microRNA mimic therapeutics
- RNAi and miRNA sequence design and optimization
- Polymer nanoparticle-based nucleic-acid delivery
Key Technologies
- microRNA mimic therapeutics
- RNAi/miRNA sequence optimization algorithms
- Polymer nanoparticle delivery (PLGA-modified PEI formulations)
- Receptor-mediated targeting of nanoparticles